A simple view of a simple man..., page-3

The amazing think about Keytruda is that it doesn’t target the cancer cells at all. It’s an antibody against PD-1, which is co-expressed on regulatory T-cells. Those T-regs inhibit the immune system from recognizing cancer cells, which it would remove if it knew they were there. Keytruda releases the breaks. The beauty of what Immutep has with efti, is that it pushes the gas on the desired immune response. The exciting thing about TACTI-002 in non small cell lung cancer, is that it’s increasing the amount of patients in a big way who benefit from Keytruda. efti is a simple inexpensive shot doing this, completely untethered to an asset like Keytruda. I believe efti will have broad use across most treatments, With Keytruda being one of dozens of settings. efti will be competitive with eventual APC activating competition because doctors and patients will prefer the inexpensive shot of efti, bang for your buck. It’s working!